🧬Gut Health & Digestion

A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.

The oral formulation of BPC-157 using the arginate salt form, designed for convenient capsule administration targeting gut healing and systemic effects without injection.

The arginine salt form of BPC-157, optimized for oral bioavailability and stability, used interchangeably with BPC-157 for tissue healing and gut repair.

A GLP-2 analog that promotes intestinal mucosal growth and adaptation, FDA-approved for short bowel syndrome to reduce dependence on parenteral nutrition.

A synthetic octapeptide that regulates intestinal tight junctions, developed as the first drug to target intestinal permeability ('leaky gut') in celiac disease and other conditions.

A naturally occurring anti-inflammatory tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH), studied for its potent anti-inflammatory effects in the gut, skin, and systemically.

A 28-amino acid neuropeptide with broad immunomodulatory, vasodilatory, and anti-inflammatory effects, used in CIRS (Chronic Inflammatory Response Syndrome) protocols and researched for pulmonary conditions.

An oral formulation of semaglutide co-formulated with the absorption enhancer SNAC, enabling GLP-1 receptor agonist therapy via daily tablet rather than weekly injection.

A synthetic octapeptide analog of somatostatin with prolonged activity, used to treat acromegaly, carcinoid tumors, and vasoactive intestinal peptide-secreting tumors.

The only human cathelicidin antimicrobial peptide, a 37-amino acid peptide beginning with two leucines, with broad-spectrum antimicrobial, anti-biofilm, immunomodulatory, and wound healing properties.

A long-acting synthetic somatostatin analog administered as a deep subcutaneous depot injection every 4 weeks for acromegaly and neuroendocrine tumors.

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.

Bioactive peptide fragments derived from hydrolyzed collagen protein that support skin elasticity, joint health, bone density, hair/nail growth, and gut lining integrity through stimulation of endogenous collagen synthesis.

A long-acting amylin receptor agonist in clinical development for obesity, designed for weekly subcutaneous injection and being studied in combination with semaglutide (CagriSema) for enhanced weight loss.

A synthetic hexapeptide growth hormone secretagogue that stimulates GH release through the ghrelin receptor (GHS-R1a), notable for its potent GH-releasing effects and strong appetite stimulation.

A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.

A first-in-class oral non-peptide GLP-1 receptor agonist in late-stage clinical development for obesity and type 2 diabetes, offering once-daily dosing without fasting requirements.

A class of ultra-short (2-4 amino acid) tissue-specific peptides developed by Prof. Vladimir Khavinson that regulate gene expression in target organs, used in Russian medicine for anti-aging and organ-specific rejuvenation.

A family of small cationic antimicrobial peptides that form a critical part of the innate immune system, providing broad-spectrum defense against bacteria, fungi, and viruses.

A DPP-4 inhibitor that prevents the enzymatic breakdown of incretin hormones GLP-1 and GIP, enhancing glucose-dependent insulin secretion for type 2 diabetes management.